HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $57 to $61.
May 13, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Tarsus Pharmaceuticals and increased the price target from $57 to $61, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong bullish sentiment on the stock, suggesting an expectation of upward price movement in the short term. This is based on the firm's analysis and confidence in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100